Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback